: The top pick for those looking at Indian markets, cited as a long-term leader in specialty drugs.
For April 2026, analysts and market data highlight several top-performing and undervalued pharmaceutical stocks driven by strong pipelines in obesity, diabetes, and oncology.
: Often recommended as a high-yield dividend play, currently viewed as undervalued by some analysts following the post-pandemic normalization of COVID-19 product sales.
: The global leader in animal health, currently ranked as an "undervalued" wide-moat stock by Morningstar.
: The top pick for those looking at Indian markets, cited as a long-term leader in specialty drugs.
For April 2026, analysts and market data highlight several top-performing and undervalued pharmaceutical stocks driven by strong pipelines in obesity, diabetes, and oncology. top pharma stocks to buy now
: Often recommended as a high-yield dividend play, currently viewed as undervalued by some analysts following the post-pandemic normalization of COVID-19 product sales. : The top pick for those looking at
: The global leader in animal health, currently ranked as an "undervalued" wide-moat stock by Morningstar. top pharma stocks to buy now